AstraZeneca (AZN) Lower, Loses Certain CRESTOR Patent Decision
Up)
AstraZeneca plc (NYSE: AZN) is ticking lower following headlines that it lost a ruling over 2018 and 2022 CRESTOR patents. Shares are down 0.7 percent.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Basilea participates in public-private collaboration to tackle antibiotic resistance
- Proctor & Gamble (PG) To Change 'Tide Pods' Design So Kids Don't Eat Them
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
Create E-mail Alert Related Categories
FDA, Insiders' Blog, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
